Quiz 51: Pharmacotherapy of Mycobacterial Infections
Tuberculosis is an opportunistic infectious disease caused by the bacteria "mycobacterium tuberculosis." The treatment of tuberculosis includes the long term multi-drug therapy. Multi-drug therapies help in the treatment of diseases caused by resistant strains and dormant organisms as they attack the organism at different stages of its development. Mycobacterium can stay dormant in the macrophages of the infected person, it becomes activated under favourable conditions, and so full type therapy is needed to prevent recurrence.
Tuberculosis is an opportunistic infection caused by the mycobacterium tuberculosis. People with decreased immune response such as those taking poor nutrition or taking immune suppressants are at an increased risk of opportunistic infections due to decreased immune functioning. For example, people taking immune suppressants such as TNF- inhibitors including the monoclonal antibodies such as infliximab, certolizumab and enteracept are reported to increase the risk of occurance of TB or recurrence of latent TB. These drugs weaken the immune response by interfering with the TNF mediate immune responses and also the innate immunity.
Tuberculosis is an infectious disease caused by the bacteria "mycobacterium tuberculosis." The mode of transmission is through the contagious air, i.e. air borne, droplet infection. The organism can enter into the body by a contaminated droplet released during coughing, laughing, sneezing or speaking. The infection commonly affects lungs but also affects other systems and organs of the body such as lymph nodes and brain. A person with TB disease hives positive result for the sputum test and exhibits the key symptoms of TB that include sudden weight loss, severe cough, fever, chills and chest pain.